Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines

Yoshio Okada, Yuko Tsuda, Keiko Wanaka, Mayako Tada, Utako Okamoto, Shosuke Okamoto, Akiko Hijikata-Okunomiya, Gyorgyi Bokonyi, Bela Szende, Gyorgy Keri

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

trans-4-Aminomethylcyclohexanecarbonyl-Tyr(O-Pic)-octylamide (YO-2) inhibited plasmin (PL) selectively, while trans-4-aminomethylcyclohexanecarbonyl-Phe-4-carboxymethylanilide (YO-1) inhibited plasma kallikrein (PK). YO-2 induced apoptosis of M1 (melanoma) cell line and HT29 colon carcinoma cells during 24 h through activation of caspase-3, while YO-1 did not affect either cell line even during 48 h. (C) 2000 Elsevier Science Ltd.

Original languageEnglish
Pages (from-to)2217-2221
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume10
Issue number19
DOIs
Publication statusPublished - Oct 2 2000

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines'. Together they form a unique fingerprint.

  • Cite this